Actuate Therapeutics Inc (ACTU)

$6.67 -0.29 (-4.17%)
Market Cap 138.60M
Revenue (ttm) 0.00
Net Income (ttm) -27.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 66,900
Avg Vol 87,236
Day's Range N/A - N/A
Shares Out 20.78M
Stochastic %K 12%
Beta N/A
Analysts Strong Sell
Price Target $20.33

Company Profile

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and color...

Industry: Biotechnology
Sector: Healthcare
Phone: 817 887 8455
Address:
1751 River Run, Suite 400, Fort Worth, United States
OpenOutcrier
OpenOutcrier Sep. 10 at 12:49 PM
$ACTU (-21.9% pre) Actuate Therapeutics prices $15 million stock offering at $7 per share https://ooc.bz/l/76814
0 · Reply
DonCorleone77
DonCorleone77 Sep. 10 at 12:45 PM
$ACTU Actuate Therapeutics 2.142M share Secondary priced at $7.00
0 · Reply
DonCorleone77
DonCorleone77 Sep. 2 at 8:32 PM
$ACTU Actuate Therapeutics files $250M mixed securities shelf
0 · Reply
Gevoallin
Gevoallin Aug. 26 at 4:19 PM
$ACTU lets goooo
0 · Reply
JarvisFlow
JarvisFlow Aug. 26 at 10:30 AM
B. Riley Securities has updated their rating for Actuate Therapeutics ( $ACTU ) to Buy with a price target of 20.
0 · Reply
benzinga
benzinga Aug. 25 at 5:55 PM
Actuate Therapeutics Advances A New Era In Oncology With Potential Universal Backbone Therapy $ACTU https://www.benzinga.com/partner/biotech/25/08/47309034/actuate-therapeutics-advances-a-new-era-in-oncology-with-potential-universal-backbone-therapy
0 · Reply
DipGlider
DipGlider Aug. 23 at 4:41 AM
$ACTU Technology company in quiet period or with minimal operations requiring careful due diligence
0 · Reply
PapaRoki
PapaRoki Aug. 13 at 8:42 PM
$ACTU
0 · Reply
white__valkyrie
white__valkyrie Aug. 10 at 5:24 PM
$ACTU next news? thank you
0 · Reply
Vito747
Vito747 Aug. 8 at 1:55 PM
$ACTU
0 · Reply
Latest News on ACTU
Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

Sep 10, 2025, 8:31 AM EDT - 4 days ago

Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

Actuate Therapeutics Announces Proposed Public Offering of Common Stock

Sep 9, 2025, 4:07 PM EDT - 5 days ago

Actuate Therapeutics Announces Proposed Public Offering of Common Stock

Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

Aug 6, 2025, 8:45 AM EDT - 5 weeks ago

Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas

Jul 17, 2025, 8:45 AM EDT - 2 months ago

Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas

Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial

Jun 24, 2025, 9:15 AM EDT - 2 months ago

Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Jun 20, 2025, 8:45 AM EDT - 3 months ago

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Jun 16, 2025, 8:30 AM EDT - 3 months ago

Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

May 31, 2025, 4:30 PM EDT - 3 months ago

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

May 22, 2025, 5:05 PM EDT - 4 months ago

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2025, 10:24 AM EDT - 5 months ago

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

Apr 17, 2025, 8:00 AM EDT - 5 months ago

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

Feb 6, 2025, 8:00 AM EST - 7 months ago

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Dec 17, 2024, 8:28 AM EST - 9 months ago

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development

Oct 29, 2024, 6:39 PM EDT - 11 months ago

Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 9:10 AM EDT - 1 year ago

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

U.S. IPO Weekly Recap: WeRide Reschedules While 6 New Filers Join The Pipeline

Aug 17, 2024, 5:10 AM EDT - 1 year ago

U.S. IPO Weekly Recap: WeRide Reschedules While 6 New Filers Join The Pipeline

CEP HCAI TDTH WRD YXT

Actuate Therapeutics Announces Closing of Initial Public Offering

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Actuate Therapeutics Announces Closing of Initial Public Offering

Actuate Therapeutics Announces Pricing of Initial Public Offering

Aug 12, 2024, 8:27 PM EDT - 1 year ago

Actuate Therapeutics Announces Pricing of Initial Public Offering

U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing

Aug 3, 2024, 12:30 AM EDT - 1 year ago

U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing

GFL OSTX

U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week

Jul 20, 2024, 4:50 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week

ARDT ARTV BLMZ CON LINE OS QMMM

Actuate Therapeutics Seeks IPO For Promising Pancreatic Cancer Drugs

May 28, 2024, 5:34 PM EDT - 1 year ago

Actuate Therapeutics Seeks IPO For Promising Pancreatic Cancer Drugs

OpenOutcrier
OpenOutcrier Sep. 10 at 12:49 PM
$ACTU (-21.9% pre) Actuate Therapeutics prices $15 million stock offering at $7 per share https://ooc.bz/l/76814
0 · Reply
DonCorleone77
DonCorleone77 Sep. 10 at 12:45 PM
$ACTU Actuate Therapeutics 2.142M share Secondary priced at $7.00
0 · Reply
DonCorleone77
DonCorleone77 Sep. 2 at 8:32 PM
$ACTU Actuate Therapeutics files $250M mixed securities shelf
0 · Reply
Gevoallin
Gevoallin Aug. 26 at 4:19 PM
$ACTU lets goooo
0 · Reply
JarvisFlow
JarvisFlow Aug. 26 at 10:30 AM
B. Riley Securities has updated their rating for Actuate Therapeutics ( $ACTU ) to Buy with a price target of 20.
0 · Reply
benzinga
benzinga Aug. 25 at 5:55 PM
Actuate Therapeutics Advances A New Era In Oncology With Potential Universal Backbone Therapy $ACTU https://www.benzinga.com/partner/biotech/25/08/47309034/actuate-therapeutics-advances-a-new-era-in-oncology-with-potential-universal-backbone-therapy
0 · Reply
DipGlider
DipGlider Aug. 23 at 4:41 AM
$ACTU Technology company in quiet period or with minimal operations requiring careful due diligence
0 · Reply
PapaRoki
PapaRoki Aug. 13 at 8:42 PM
$ACTU
0 · Reply
white__valkyrie
white__valkyrie Aug. 10 at 5:24 PM
$ACTU next news? thank you
0 · Reply
Vito747
Vito747 Aug. 8 at 1:55 PM
$ACTU
0 · Reply
Vito747
Vito747 Jul. 25 at 12:51 PM
$ACTU
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 25 at 12:12 AM
$ACTU Outstanding article that hits the mark on ACTU's current state. So if you want to refresh your ACTU insights or learn about ACTU from scratch, this is a must read. https://beyondspx.com/article/actuate-therapeutics-elraglusib-s-phase-2-breakthrough-ignites-hope-amidst-urgent-funding-needs-nasdaq-actu
0 · Reply
Vito747
Vito747 Jul. 24 at 9:00 PM
$ACTU Actuate plans to further investigate elraglusib’s ability to positively change patients’ potential for successful treatment in a Phase 2 trial in pediatric, adolescent, and adult patients with relapsed/refractory Ewing Sarcoma
0 · Reply
Vito747
Vito747 Jul. 24 at 8:59 PM
$ACTU
0 · Reply
Vito747
Vito747 Jul. 23 at 8:10 AM
$ACTU 10% up from my previous message overnight… don t sleep on $ACTU
0 · Reply
Vito747
Vito747 Jul. 23 at 8:09 AM
$ACTU
0 · Reply
Vito747
Vito747 Jul. 23 at 8:09 AM
$ACTU This is the pre-pump phase ACTU is coiling up big time.
0 · Reply
Vito747
Vito747 Jul. 22 at 8:05 PM
$ACTU H.C. Wainwright reiterates BUY with $20 PT after Phase 1/2 Ewing Sarcoma success – 250% upside from $5.8 💎 $ACTU
0 · Reply
Vito747
Vito747 Jul. 22 at 8:04 PM
$ACTU insiders bought 71,428 shares each at $7 on June 27 — $1.5M total – ultimate confidence! 🚀 $ACTU
0 · Reply
Vito747
Vito747 Jul. 22 at 8:03 PM
$ACTU Tiny float + upcoming data = ACTU moonshot
0 · Reply
Vito747
Vito747 Jul. 22 at 8:02 PM
$ACTU Low cap biotech with real pipeline , ACTU can explode fast
0 · Reply
Vito747
Vito747 Jul. 21 at 3:25 PM
$ACTU
0 · Reply